



This is a repository copy of *Sex-specific cardiac magnetic resonance pulmonary capillary wedge pressure*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/212636/>

Version: Published Version

---

**Article:**

Garg, P. [orcid.org/0000-0002-5483-169X](https://orcid.org/0000-0002-5483-169X), Grafton-Clarke, C., Matthews, G. [orcid.org/0000-0001-8353-4806](https://orcid.org/0000-0001-8353-4806) et al. (8 more authors) (2024) Sex-specific cardiac magnetic resonance pulmonary capillary wedge pressure. *European Heart Journal Open*, 4 (3). ISSN 2752-4191

<https://doi.org/10.1093/ehjopen/oeae038>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

# Sex-specific cardiac magnetic resonance pulmonary capillary wedge pressure

Pankaj Garg <sup>1,2,\*</sup>, Ciaran Grafton-Clarke<sup>1,2</sup>, Gareth Matthews <sup>1,2</sup>, Peter Swoboda<sup>3</sup>, Liang Zhong<sup>4,5</sup>, Nay Aung <sup>6</sup>, Ross Thomson<sup>6</sup>, Samer Alabed <sup>7,8</sup>, Ahmet Demirkiran <sup>9,10</sup>, Vassilios S. Vassiliou <sup>1,2</sup>, and Andrew J. Swift<sup>7,8,11</sup>

<sup>1</sup>Norwich Medical School, University of East Anglia, Norwich Research Park, Rosalind Franklin Road, Norwich NR4 7UQ, UK; <sup>2</sup>Department of Cardiology, Norfolk and Norwich University NHS Foundation Trust, Colney Lane, Norwich NR4 7UY, UK; <sup>3</sup>Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK; <sup>4</sup>National Heart Research Institute Singapore, National Heart Centre Singapore, 5 Hospital Drive, Singapore; <sup>5</sup>Signature Programme of Cardiovascular Metabolic and Disorders, Duke-NUS Medical School, 8 College Road, Singapore; <sup>6</sup>William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, UK; <sup>7</sup>National Institute for Health and Care Research, Sheffield Biomedical Research Centre, Sheffield, UK; <sup>8</sup>Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK; <sup>9</sup>Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands; <sup>10</sup>Department of Cardiology, Kocaeli City Hospital, Kocaeli, Turkey; and <sup>11</sup>INSIGNEO, Institute for in silico Medicine, University of Sheffield, Sheffield, UK

Received 3 January 2024; revised 23 April 2024; accepted 28 April 2024; online publish-ahead-of-print 15 May 2024

Handling Editor: Ana G. Almeida

## Aims

Heart failure (HF) with preserved ejection fraction disproportionately affects women. There are no validated sex-specific tools for HF diagnosis despite widely reported differences in cardiac structure. This study investigates whether sex, as assigned at birth, influences cardiac magnetic resonance (CMR) assessment of left ventricular filling pressure (LVFP), a hallmark of HF agnostic to ejection fraction.

## Methods and results

A derivation cohort of patients with suspected pulmonary hypertension and HF from the Sheffield centre underwent invasive right heart catheterization and CMR within 24 h of each other. A sex-specific CMR model to estimate LVFP, measured as pulmonary capillary wedge pressure (PCWP), was developed using multivariable regression. A validation cohort of patients with confirmed HF from the Leeds centre was used to evaluate for the primary endpoints of HF hospitalization and major adverse cardiovascular events (MACEs). Comparison between generic and sex-specific CMR-derived PCWP was undertaken. A total of 835 (60% female) and 454 (36% female) patients were recruited into the derivation and validation cohorts respectively. A sex-specific model incorporating left atrial volume and left ventricular mass was created. The generic CMR PCWP showed significant differences between males and females ( $14.7 \pm 4$  vs.  $13 \pm 3.0$  mmHg,  $P > 0.001$ ), not present with the sex-specific CMR PCWP ( $14.1 \pm 3$  vs.  $13.8$  mmHg,  $P = 0.3$ ). The sex-specific, but not the generic, CMR PCWP was associated with HF hospitalization (hazard ratio 3.9,  $P = 0.0002$ ) and MACE (hazard ratio 2.5,  $P = 0.001$ ) over a mean follow-up period of  $2.4 \pm 1.2$  years.

## Conclusion


Accounting for sex improves precision and prognostic performance of CMR biomarkers for HF.

\* Corresponding author. Tel: +44 1603 592534, Email: [p.garg@uea.ac.uk](mailto:p.garg@uea.ac.uk)

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

## Graphical Abstract



## Keywords

Sex • Heart failure • CMR

## Introduction

There is an urgent need for the development of distinct strategies to improve the diagnosis and treatment of heart disease in women.<sup>1</sup> Heart failure (HF) is a growing global health concern with an estimated prevalence of over 64 million individuals worldwide.<sup>2</sup> The exact number of these who are women is understudied and therefore uncertain. However, women suffer disproportionately from HF with preserved ejection fraction (HFpEF) due to risk factors such as aging and hypertension.<sup>3</sup> The use of ejection fraction (EF) to classify HF sub-phenotypes is extensively adopted clinically but increasingly recognized to have significant drawbacks.<sup>4</sup> The therapeutic options for HFpEF are therefore more limited than for HF with reduced ejection fraction (HFrEF),<sup>5</sup> thus driving healthcare inequality. Women are less likely to be referred for specialist HF care<sup>6</sup> or to receive optimized guideline therapy<sup>7,8</sup> and, as a result, report lower quality of life independent of EF or natriuretic peptide level.<sup>8,9</sup> Sex-specific differences in cardiac imaging<sup>10</sup> and circulating biomarkers have previously been described.<sup>11</sup>

Heart failure is a clinical diagnosis made from clinical signs and symptoms, in the context of structural or functional cardiac impairment.<sup>12</sup> Left ventricular (LV) filling pressure (LVFP) is a fundamental, physiological measure of HF, which directly drives congestive symptoms.

The gold standard measurement of LVFP is invasively conducted during cardiac catheterization either directly as the LV end-diastolic pressure or indirectly during right heart catheterization (RHC) as the pulmonary capillary wedge pressure (PCWP). These methods are laborious and carry procedural risk to the patient, limiting their widespread adoption. Non-invasive estimation of LVFP is therefore crucial in the diagnosis and management of HF.<sup>12</sup> While echocardiography remains the mainstay for non-invasive estimation of LVFP,<sup>13</sup> cardiovascular magnetic resonance (CMR) has also recently been used.<sup>14</sup> Cardiovascular magnetic resonance already plays an important role in sub-phenotyping HF,<sup>15–17</sup> making it a useful non-invasive tool in the diagnostic workflow of all patients with suspected HF.

Cardiovascular magnetic resonance–derived PCWP has been shown to have prognostic utility.<sup>14,18</sup> It is superior to transthoracic echocardiography in correctly classifying patients as having ‘normal’ or ‘raised’ filling pressures and can better determine the risk of cardiovascular death. Other large HF cohort studies have demonstrated the clinical significance of raised CMR-derived PCWP,<sup>19</sup> showing that elevated CMR-derived PCWP is strongly associated with symptoms (orthopnoea, breathlessness) and signs of HF (pleural effusions, lower limb oedema). Furthermore, raised CMR-derived PCWP is independently associated with subsequent HF hospitalization and major adverse

cardiovascular events (MACEs).<sup>19</sup> In addition to its role in HF, CMR-derived PCWP can also be used to measure acute and dynamic changes in preloading conditions on the LV during adenosine-administered first-pass perfusion CMR, where it has been observed to rise significantly.<sup>20</sup>

The CMR-derived PCWP estimation has been independently shown to correlate well with invasively measured pressures, with good accuracy for HFpEF diagnosis; however, it may overestimate PCWP at rest and underestimate it during exercise.<sup>21</sup> This highlights the need for refinement of the equation, and concerns have been raised regarding the use of LV mass (LVM) and left atrial volume (LAV) to estimate PCWP. Both these indices are sex dependent; hence, CMR-derived PCWP may overestimate PCWP in males and underestimate PCWP in females. This may affect the diagnostic precision of CMR-derived PCWP resulting in overdiagnosis of HF in men and under-diagnosis in women.

The aim of this study was to investigate whether CMR-derived PCWP is sex dependent, develop sex-specific CMR models to estimate PCWP, and to investigate whether a novel sex-specific CMR-modelled PCWP is prognostically significant.

## Methods

### Study population

In all participants, HF was diagnosed according to the European Society of Cardiology guidelines for HF<sup>12</sup> and pulmonary hypertension.<sup>22</sup> Specifically, this requires the presence of at least one symptom (e.g. breathlessness) and one clinical sign (e.g. peripheral oedema) of HF, as well as objective evidence of cardiac dysfunction (i.e. reduced EF or diastolic dysfunction on echocardiography). Two cohorts of patients were included: a derivation cohort (ASPIRE registry, Sheffield, UK) and a validation cohort (Leeds, UK). The ASPIRE registry is composed of patients with suspected pulmonary hypertension referred to Sheffield Teaching Hospitals NHS Foundation Trust, which includes all World Health Organization (WHO) groups, referred over 8 years (2012–20). Patient phenotype is extensively investigated using imaging and RHC measurements, with subsequent biomarker and pulmonary function investigations performed where appropriate. Right heart catheterization data allowed differentiation between WHO Group 2 pulmonary hypertension secondary to left heart disease and pre-capillary pulmonary hypertension, with CMR allowing investigation of cardiac dysfunction. The RHC and CMR were performed within 24 h, limiting haemodynamic changes. For the validation cohort, cardiology clinic patients with a new diagnosis of HF<sup>12</sup> in the preceding 12 months were prospectively recruited (2018–20) and underwent CMR evaluation. Diastolic dysfunction was diagnosed as per the British Society of Echocardiography guidelines. Exclusion criteria were primary pulmonary arterial hypertension, significant valvular heart disease, and contraindications to CMR (e.g. inability to lie flat, claustrophobia, and end-stage HF). Sex was physician reported as a binary male or female category, referring to the sex assigned at birth rather than the gender identity or karyotype of the patient. Reporting adhered to the SAGER guidelines.<sup>23</sup> The study was approved by Sheffield Teaching Hospitals and the UK National Research Ethics Service (16/YH/0352 and 17/YH/0300) and complied with the Declaration of Helsinki.<sup>24</sup>

### Invasive study

A balloon-tipped 7.5 French thermodilution catheter (Becton-Dickinson, Franklin Lakes, NJ) was used to perform the RHC. The PCWP was recorded using standard techniques and averaged over multiple cardiac cycles to avoid overestimating it.<sup>25</sup> The recording was made when the patients were relaxed and had minimal beat-to-beat variation.

### Cardiovascular magnetic resonance study

For the derivation group, imaging procedures involved the utilization of a 1.5T whole-body GE HDx scanner (GE Healthcare, Milwaukee, USA), while the validation cohort utilized a 3.0T Siemens Magnetom Prisma scanner (Siemens, Erlangen, DE). Cine images were captured in four-chamber (4Ch), two-chamber (2Ch), three-chamber (3Ch), and short-axis (SA)

orientations. This was achieved using a retrospective electrocardiogram-gated multi-slice steady-state free precession sequence, adhering to standard protocols (Figure 1).<sup>26</sup> Blinded offline image analysis was conducted using either the GE Advantage Workstation 4.1 or Circle cvi42 (Circle Cardiovascular Imaging, Calgary, CA).

Manual delineation of endocardial and epicardial surfaces, excluding papillary muscles, was carried out on the stack of SA cine images. This facilitated the computation of various cardiac volumes, including LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), right ventricular (RV) end-diastolic volume (RVEDV), and RV end-systolic volume (RVESV). Left ventricular stroke volume (LVSV), LVEF, RV stroke volume (RVSV), and RVEF were derived from these volumes using standard formulae. Left ventricular mass was derived using the SA cine stack at end-diastole. For left atrial assessment, the endocardium was contoured in both 4Ch and 2Ch views, enabling the determination of maximum LAV just before mitral valve opening (LV end-systolic phase) using the biplane area-length method.

### Outcome measures

For the validation cohort, patient outcomes were evaluated by reviewing electronic hospital records for MACE and hospitalization due to HF. Major adverse cardiovascular event was defined as the composite of cardiovascular death, HF hospitalization, non-fatal stroke, and non-fatal myocardial infarction.

### Statistical analysis


All clinically acquired data were normally distributed. Continuous variables were presented as mean  $\pm$  standard deviation. Categorical data were reported as frequencies and percentages. A two-sample independent *t*-test was used to compare continuous variables. The  $\chi^2$  test was used for categorical data. A paired *t*-test was used to compare sex differences in invasive PCWP vs. CMR-modelled PCWP.

Within the derivation cohort, multivariable linear regression (ENTER method) was used for each sex to generate partial correlation coefficients (using all other variables as covariates) for individual CMR metrics compared with PCWP measurement by RHC. Stepwise multivariable regression was then used to develop a sex-specific CMR-derived PCWP model. The sex-specific CMR model was applied to the validation cohort, and receiver operating characteristic analysis was performed to assess the diagnostic power of CMR-derived PCWP to detect raised RHC PCWP (defined a priori as  $>15$  mmHg). Kaplan–Meier analysis and Cox proportional hazard model were used for multivariable analysis of prognosis. Statistical analysis was performed in SPSS version 22 (IBM, Chicago, USA) and confirmed in MedCalc (MedCalc Software, Ostend, Belgium version 19.1.5). Unless otherwise stated, all statistical tests were two tailed, and a *P*-value of  $<0.05$  was deemed significant. Graphical representations were created in OriginLab (OriginLab Corporation, Northampton, MA, USA).

## Results

### Study population (derivation cohort)

A total of 835 participants were included within the derivation cohort, and 60% were female. The patient characteristics are summarized in Table 1. Both sexes had similar ages ( $66 \pm 13$  years,  $P = 0.84$ ). Females exhibited a significantly lower mean body surface area (BSA) than males ( $1.8 \pm 0.2$  vs.  $2.0 \pm 0.2$  m<sup>2</sup>,  $P < 0.0001$ ). Females had higher systolic blood pressure than males ( $146 \pm 28$  vs.  $140 \pm 24$  mmHg,  $P < 0.001$ ). Females displayed a slightly higher mean heart rate than males ( $72 \pm 15$  vs.  $70 \pm 16$  b.p.m.,  $P = 0.02$ ). There was a lower prevalence of chronic obstructive pulmonary disease in females than in males (9% vs. 15%,  $P = 0.005$ ). As expected, HFpEF was more common in females than males (62% vs. 40%,  $P < 0.001$ ), while males had more HF with mid-range EF (7% vs. 2%,  $P < 0.001$ ). There was no significant difference between invasive mean PCWP between females and males ( $14.0 \pm 6$  vs.  $13.7 \pm 6$  mmHg,  $P = 0.52$ ).



**Figure 1** Study protocol. Within the derivation cohort, 835 subjects (Sheffield centre) were referred over an 8-year period (2012–20) for further assessment of breathlessness. Cardiovascular magnetic resonance and right heart catheterization were performed within 24 h of each other. A sex-specific cardiovascular magnetic resonance–derived pulmonary capillary wedge pressure equation was derived, which included left ventricular mass and left atrial volume as cardiovascular magnetic resonance metrics. Within the validation cohort, 434 subjects (Leeds centre) with a diagnosis of heart failure in the preceding 12 months underwent cardiovascular magnetic resonance. The sex-specific cardiovascular magnetic resonance–derived pulmonary capillary wedge pressure equations were applied. CMR, cardiac magnetic resonance; PCWP, pulmonary capillary wedge pressure; RHC, right heart catheterization.

## Cardiovascular magnetic resonance evaluation (derivation cohort)

Differences between males and females in CMR volumetric and functional assessment are detailed in [Table 1](#) for the derivation cohort. Females had lower LVEDV and LVESV, resulting in smaller LVSV and higher LVEF, than males. Males demonstrated higher LVM and LAV ([Figure 2](#)). In the RV, females had a lower RVEDV, RVESV, RVSV but a higher overall RVEF. Generic CMR-derived PCWP<sup>14</sup> values were significantly higher in males ( $14.7 \pm 4.0$  vs.  $13.0 \pm 3.0$  mmHg,  $P < 0.001$ ) compared to females.

## Cardiovascular magnetic resonance link to invasive assessment of pulmonary capillary wedge pressure (derivation cohort)

Out of all the CMR variables, CMR-derived LAV was most strongly associated with mean invasive PCWP in both sexes ([Table 2](#)). Due to the interdependence of CMR variables with each other, we further investigated the independent association of each parameter to invasive PCWP using ENTER multiple regression. Here again, LAV (females: partial  $r = 0.45$ ,  $P < 0.001$ ; males: partial  $r = 0.49$ ,  $P < 0.001$ ) and LVM (females: partial  $r = 0.16$ ,  $P < 0.001$ ; males: partial  $r = 0.13$ ,  $P = 0.02$ ) were independently associated with invasive PCWP in both sexes, even after factoring in all other variables as covariates ([Figure 3](#)). The pattern of association between LVM, LAV, and invasive PCWP is sex specific, as demonstrated in [Figure 4](#).

## Sex-specific cardiovascular magnetic resonance–derived pulmonary capillary wedge pressure (derivation cohort)

Sex, LAV, and LVM were used as the three input variables in stepwise multivariable regression, with age as a weighted variable. The following sex-specific equation was determined with goodness of fit ( $R$ -value) of 0.571:

$$\text{CMR PCWP} = 5.7591 + (0.07505 \cdot \text{LAV}) + (0.05289 \cdot \text{LVM}) - (1.9927 \cdot \text{sex}) [\text{female} = 0; \text{male} = 1].$$


Given the systematic difference in BSA between males and females, indexed volumetrics and BSA directly were also tried in the model (see [Supplementary material online, Appendix S1](#)). However, indexed LAV and LVM values gave a worse goodness of fit ( $R = 0.470$ ) and did not remove the independent influence of sex; hence, the non-indexed equation was selected.

## Internal cross-validation (derivation cohort)

In multiple stepwise regression, the novel sex-specific model retained its independent association with invasively measured PCWP, whereas the previously used generic CMR-derived model was excluded ( $\beta = 1$ , standard error = 0.005,  $P < 0.0001$ , partial  $r = 0.57$ ). In paired comparisons between invasive and generic CMR-derived

**Table 1** Patient characteristics, cardiac magnetic resonance imaging assessment, and pulmonary capillary wedge pressure assessment stratified by sex

	Female sex (n = 497)	Male sex (n = 338)	P-value
Age (years)	66 ± 13	66 ± 13	0.84
Body surface area (m <sup>2</sup> )	1.8 ± 0.2	2.0 ± 0.2	<0.0001
Heart rate (b.p.m.)	72 ± 15	70 ± 16	0.02
Chronic obstructive pulmonary disease, n (%)	45 (9)	52 (15)	0.005
Heart failure preserved ejection fraction, n (%)	306 (62)	136 (40)	<0.0001
Heart failure mid-range ejection fraction, n (%)	10 (2)	22 (7)	<0.001
Heart failure reduced ejection fraction, n (%)	12 (2)	11 (3)	0.47
Other, n (%)	169 (34)	169 (50)	<0.0001
<b>Cardiac magnetic resonance imaging data</b>			
Heart rate (b.p.m.)	77 ± 14.0	74 ± 14	0.0004
Systolic blood pressure (mmHg)	146 ± 28	140 ± 24	<0.001
Diastolic blood pressure (mmHg)	78 ± 12	78 ± 14	0.32
Left ventricular end-diastolic volume (mL)	103 ± 30	121 ± 43	<0.0001
Left ventricular end-systolic volume (mL)	32 ± 17	45 ± 24	<0.0001
Left ventricular stroke volume (mL)	71 ± 22	76 ± 27	0.001
Left ventricular ejection fraction (%)	69 ± 11	63 ± 11	<0.0001
Left ventricular mass (g)	84 ± 24	118 ± 36	<0.0001
Left atrial volume (mL)	75 ± 39	82 ± 49	0.01
Right ventricular end-diastolic volume (mL)	131 ± 52	173 ± 67	<0.0001
Right ventricular end-systolic volume (mL)	71 ± 40	106 ± 53	<0.0001
Right ventricular stroke volume (mL)	60 ± 24	67 ± 29	<0.001
Right ventricular ejection fraction (%)	47 ± 13	40 ± 13	<0.0001
<b>PCWP assessment</b>			
Invasive PCWP (mmHg)	14.0 ± 6.0	13.7 ± 6.0	0.5
Generic CMR-derived PCWP	13.0 ± 3.0	14.7 ± 4.0	<0.001
Sex-specific CMR-derived PCWP	14.1 ± 3.0	13.8 ± 4.0	0.3

**Figure 2** Within the derivation cohort (n = 835), left atrial volume and left ventricular mass were significantly lower in females than in males.

PCWP, the generic equation underestimated PCWP in females ( $14.0 \pm 6.0$  vs.  $13.0 \pm 3.0$  mmHg,  $P = 0.01$ ) and overestimated PCWP in males ( $13.7 \pm 6.0$  vs.  $14.7 \pm 4.0$  mmHg,  $P < 0.001$ , Figure 5). In contrast, PCWP did not differ significantly between invasive assessment and sex-specific CMR equation.

### Validation within an external heart failure cohort

The above equations were applied to the validation cohort (n = 454, 36% female) to estimate PCWP. From this population, 52% (n = 240)

had HFpEF, and the rest had HFrEF (48%,  $n = 214$ ). In both HFpEF and HFrEF, the generic CMR equation demonstrated a significant difference in derived PCWP between males and females ( $P < 0.001$ , Figure 6). However, when utilizing sex-specific CMR-derived PCWP values, no statistically significant difference was observed between females and males ( $14.1 \pm 3.0$  vs.  $13.8 \pm 4.0$  mmHg respectively,  $P = 0.3$ ), indicating resolution of the previous sex-specific bias in the generic equation (Figure 6).

### Survival analysis for heart failure hospitalization (validation cohort)

During a mean follow-up period of  $2.4 \pm 1.2$  years, 38 (8.4%) patients were hospitalized with decompensated HF. In multivariable Cox proportional hazard regression, factoring in both raised generic and sex-specific CMR-derived PCWP ( $>15$  mmHg), only the sex-specific model

demonstrated independent association to HF hospitalization [beta = 1.4, standard error = 0.37,  $P = 0.0002$ , hazard ratio (HR) 3.9, 95% confidence interval (CI) 1.9–8.0]. In Kaplan–Meier analysis, sex-specific CMR-modelled PCWP was predictive of survival for both males and females ( $\chi^2 = 15.7$ ,  $P = 0.0001$ , Figure 7).

### Survival analysis for major adverse cardiovascular event (validation cohort)

During a mean follow-up period of  $2.4 \pm 1.2$  years, 56 (12.3%) patients had MACE. In multivariable Cox proportional hazard regression factoring in both raised generic and sex-specific CMR-derived PCWP ( $>15$  mmHg), only the sex-specific model demonstrated independent association to MACE (beta = 0.92, standard error = 0.23,  $P = 0.001$ , HR 2.5, 95% CI 1.4–4.3). Cut-off values for CMR PCWP were not different between HFpEF or HFrEF groups (see Supplementary material online, Appendix S2). In Kaplan–Meier analysis, sex-specific CMR-modelled PCWP was predictive for MACE ( $\chi^2 = 11.4$ ,  $P = 0.0007$ , Figure 7).


Cardiovascular magnetic resonance PCWP remained predictive when LVEF was also factored into the analysis for both MACE and HF hospitalizations, suggesting that it was an independent outcome predictor across all HF classifications (see Supplementary material online, Appendix S3).

**Table 2** Correlation between cardiovascular magnetic resonance variables and mean invasive pulmonary capillary wedge pressure in males and females within the derivation cohort


	Females		Males	
	R	P-value	R	P-value
Left ventricular end-diastolic volume	0.31	<0.0001	0.36	<0.0001
Left ventricular end-systolic volume	0.22	<0.0001	0.30	<0.0001
Left ventricular stroke volume	0.24	<0.0001	0.30	<0.0001
Left ventricular ejection fraction	−0.06	0.2	−0.06	0.3
Left ventricular mass	0.29	<0.0001	0.33	<0.0001
Left atrial volume	0.54	<0.0001	0.58	<0.0001
Right ventricular end-diastolic volume	0.21	<0.0001	0.11	0.05
Right ventricular end-systolic volume	0.11	0.01	0.02	0.74
Right ventricular stroke volume	0.27	<0.0001	0.21	0.0001
Right ventricular ejection fraction	0.07	0.1	0.10	0.08

## Discussion


The present study investigates the impact of sex on cardiac imaging methods of HF assessment. Women are exposed to different biological, psychosocial, and socioeconomic risk factors compared with men, particularly on a global scale,<sup>1</sup> and it is therefore important to ensure measurement validity in both sexes. A novel sex-specific equation for LVFP estimation is validated and demonstrates superior performance. The previously derived generic CMR-derived PCWP equation overestimated PCWP in males and underestimated PCWP in females: potentially resulting in over- and under-diagnosis, respectively, especially in early or borderline disease. The novel CMR sex-specific PCWP equation resolves this issue. Both during internal cross-validation and validation within a large external cohort of HF patients, the sex-specific



**Figure 3** Radial line plot demonstrating that within the derivation cohort ( $n = 835$ ), left atrial volume and left ventricular mass were significantly associated with invasively measured pulmonary capillary wedge pressure during partial correlation analysis.



**Figure 4** 3D surface plot showing sex-specific profiles in the relationship between left ventricular mass, left atrial volume, and invasive mean pulmonary capillary wedge pressure within the derivation cohort ( $n = 835$ ).




**Figure 5** Within the derivation cohort, the difference in assessment between invasive and generic cardiovascular magnetic resonance–derived pulmonary capillary wedge pressure was significant across both sexes. There was no statistical difference between the invasive and sex-specific cardiovascular magnetic resonance–derived pulmonary capillary wedge pressure.

CMR-derived PCWP model had superior prognostic capabilities for HF hospitalization and MACE.

The elegance of previous CMR-derived PCWP estimation has been that it uses two robust anatomical measurements: LVM, a marker of afterload, and LAV, a marker of preload, on the LV. However, it is also established that both these CMR-derived parameters are lower

in females than in males,<sup>27</sup> reflecting innate biological differences not necessarily related to loading conditions. It is therefore logical that these prior differences should be accounted for to allow dynamic LVM and LAV variations to accurately reflect the underlying haemodynamic state. There are well-accepted differences in body habitus between males and females at a population level, and indexing is often



**Figure 6** Within the validation cohort, pulmonary capillary wedge pressure assessment using the sex-specific model resulted in comparable mean pulmonary capillary wedge pressure between sexes, which was not the case using the generic cardiovascular magnetic resonance–derived pulmonary capillary wedge pressure model. This finding was sustained in both heart failure with preserved and reduced LV function.

used to improve comparability of single volumetric measurements.<sup>28</sup> There are however concerns about the best measure to use for indexing, particularly in certain populations such as obesity.<sup>29–31</sup> Obesity is common in HFpEF and cardiovascular conditions in general.<sup>32</sup> In the present study, we did not find improvement in the model for BSA indexed values, and sex continued to be an independent modifier despite adjustment. This might suggest that biological sex is more important than simple differences in body size. In composite measures with multiple indexed values, the additional variable might also introduce measurement error greater than any added value it provides for prediction.

The ASPIRE registry represents a mixed population with HF, pulmonary disease, and pre-capillary pulmonary hypertension and includes a range of normal and abnormal PCWPs. This heterogeneity is ideal for the derivation of a CMR PCWP allowing for a range of filling pressures in both cardiac and non-cardiac disease, with similar clinical symptoms, with high external validity. The Leeds registry provides a well phenotyped cohort of ischaemic and non-ischaemic cardiomyopathy, reflective of everyday practice, and enhancing outcome generalizability.

Left atrial volume provides a sensitive marker of underlying haemodynamics. In normal physiological conditions, an increase in preload (such as during exercise or volume overload) leads to an increase in LAV. This distension results in more forceful LA contraction, maintaining efficient blood flow into the LV.<sup>33</sup> However, in pathological conditions such as HF, the relationship between preload and LAV can be altered. For instance, in HFpEF, the LV becomes stiff and less compliant, leading to increased LVFP.<sup>34</sup> This increased pressure is reflected into the left atrium, causing LA enlargement.<sup>35</sup> Furthermore, studies have shown that acute changes in preload can also affect LAV.<sup>20</sup> Left atrial function, at both rest and during exercise stress, has emerged as the strongest predictor of cardiovascular outcomes in the HFpEF stress trial.<sup>36</sup> In a sub-analysis of this study, the resting LAV was different between males and females, and the changes in LA EF and LA filling reserve were significantly impaired in women with HFpEF.<sup>37</sup> The LV filling pressure has also been shown to increase significantly in HFpEF patients with an EF >60% with exercise, with this subgroup likely reflecting a hypercontractile state secondary to high afterload.<sup>38</sup> The present study adds weight to the concept of left atrial disease and elevated intracardiac pressures being central to HFpEF physiology in this large outcomes cohort.


This is also the first study that explores the associations of invasively measured PCWP with both left and right heart CMR-derived parameters. Interestingly, we find that LAV and LVM remain the most predictive variables in females. In males, RVEF and LVESV also showed some minor association. Left ventricular hypertrophy (LVH) is a complex adaptive response to increased afterload,<sup>39</sup> predominantly occurring in conditions such as systemic hypertension and aortic stenosis,<sup>40,41</sup> entailing a cascade of cellular and molecular alterations to accommodate the augmented mechanical workload.<sup>42</sup> Myocyte hypertrophy, a hallmark of LVH, ensues from cellular signalling pathways leading to enhanced contractile protein synthesis, thereby augmenting the force-generating capacity of cardiomyocytes.<sup>43</sup> Activation of growth factors such as angiotensin II and transforming growth factor-beta (TGF- $\beta$ ) contributes to fibroblast proliferation and extracellular matrix remodelling.<sup>44</sup> Fibrosis promotes myocardial stiffness and structural alterations—both of which are the hallmarks of LV diastolic dysfunction. In many instances, load-induced LVH is treatable, and hence, the CMR-derived PCWP is a novel therapeutic biomarker in patients with HF.<sup>45</sup>

The present work is unable to comment specifically on the clinical management for HFpEF, as its scope was diagnostic. However, it is hypothesis generating that treatments, such as SGLT2 inhibitors, might be more efficacious when personalized to those with raised filling pressures. Other works sub-phenotyping HFpEF have suggested similar strategies for this heterogeneous group.<sup>38</sup>

## Limitations

In the derivation cohort, there is the possibility of selection bias as this study was undertaken at a tertiary centre that took referrals for RHC assessment, potentially limiting recruitment of the very elderly or frail. However, it is noteworthy that our study stands as one of the largest investigations that encompassed a diverse cohort of patients, aiming to explore PCWP using CMR. All patients included were clinically stable seeking care for breathlessness in an outpatient setting and did not encompass acute HF patients; hence, it remains to be seen if the methods established here are applicable in the latter situation.

The study was conducted in a broad cohort of HF patients with predominantly ischaemic or non-ischaemic cardiomyopathy. We have not



sought to validate the equation in specific aetiologies of HF where study power would be much reduced. The results should not therefore be applied to significant valvular heart disease, as such patients were excluded from both the derivation and validation cohorts, and because there might be different courses of LAV and LVM changes in these patients, particularly in regurgitant lesions. The sex-specific CMR PCWP is more dependent on LAV than LVM; therefore, we hypothesize it would be useful in infiltrative and hypertrophic cardiomyopathies, where there is increasing evidence that changes in LAV are both part of the progression of disease and also prognostic.<sup>46–51</sup> Further studies are required to validate the sex-specific CMR PCWP specifically in each of these aetiologies. The results of this study should also not be applied to athletes who have a higher LVM and LAV due to positive remodelling, compared to adverse remodelling in patients with high PCWP, without further validation.

The RHC and CMR data were obtained at rest, rather than with exercise stress, in this study. There is increasing evidence of abnormal physiological response of cardiac function and volumetrics to exercise in HFpEF,<sup>52</sup> particularly in women.<sup>37</sup> It is therefore possible that such cases would be missed or inconclusive using the present method, and that exercise-related measures might improve prediction of PCWP. However, adding exercise stress into routine CMR acquisition is more technically challenging, time consuming, and expensive, with most CMR imaging worldwide conducted in the resting state only. The present approach would potentially identify cohorts with raised PCWP at rest, allowing resources for exercise stress to be focused on marginal cases.

Sex assigned at birth was utilized in this study rather than karyotype or gender identity; hence, the results may not be applicable in intersex individuals or those who have chosen an alternative gender. There has been a marked increase in the number of young people identifying a transgender identity.<sup>53</sup>

## Conclusions

A sex-specific CMR-modelled LVFP improves the precision of PCWP estimation and prognostic performance in patients with HF.

## Lead author biography



Dr Pankaj Garg is an associate professor in cardiovascular medicine at the University of East Anglia, Norwich, UK, and honorary consultant cardiologist at Norfolk and Norwich University Hospitals. He graduated in medicine with honours from I.M. Sechenov (2003) and became a member of the Royal College of Physicians in 2007. After completing his BHF-funded PhD at Leeds (2017), he was awarded the NIHR Clinical Lectureship programme at the University of Sheffield. In 2020,

he was awarded Wellcome Trust Clinical Research Career Development Fellowship. His research focus is cardiovascular haemodynamics and cardiac magnetic resonance imaging. His ambition is to discover and advance a better understanding of the interface between cardiovascular flow and cardiac remodelling. He has received 20 national/international awards and has published >185 peer-reviewed papers.

## Data availability

Deidentified data underlying this article will be shared on reasonable request to the corresponding author for further academic study following

publication. As this is a multicentre study, agreement would be required from all contributing centres.

## Supplementary material

Supplementary material is available at *European Heart Journal Open* online.

## Ethical approval

This study complies with the Declaration of Helsinki.

## Authors' contribution

All authors contributed to the manuscript and had full access to the underlying data.

## Acknowledgements

We thank the clinical teams at Sheffield and Leeds centres for providing substantive support with right heart catheter invasive studies.

## Funding

This study or research is funded by the National Institute for Health and Care Research (NIHR) Sheffield Biomedical Research Centre (NIHR203321\*), the Wellcome Trust (220703/Z/20/Z and 215799/Z/19/Z), and the National Medical Research Council (NMRC/OFIRG/0018/2016). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care, Wellcome Trust, or NMRC.

**Conflict of interest:** P.G. is a clinical advisor for Pie Medical Imaging and Medis Medical Imaging. All other authors have no conflicts of interest to declare.

## References

- Vogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA, Guerrero M, Kunadian V, Lam CSP, Maas AHEM, Mihailidou AS, Olszanecka A, Poole JE, Saldarriaga C, Saw J, Zühlke L, Mehran R. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. *Lancet Lond Engl* 2021;**397**: 2385–2438.
- Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. *Cardiovasc Res* 2023;**118**:3272–3287.
- Lam CSP, Arnott C, Beale AL, Chandramouli C, Hilfiker-Kleiner D, Kaye DM, Ky B, Santema BT, Sliwa K, Voors AA. Sex differences in heart failure. *Eur Heart J* 2019;**40**: 3859–3868c.
- Marwick TH. Ejection fraction pros and cons. JACC state-of-the-art review. *J Am Coll Cardiol* 2018;**72**:2360–2379.
- Xiang B, Zhang R, Wu X, Zhou X. Optimal pharmacologic treatment of heart failure with preserved and mildly reduced ejection fraction: a meta-analysis. *JAMA Netw Open* 2022;**5**:e2231963.
- Feldman DE, Huynh T, Des Lauriers J, Giannetti N, Frenette M, Grondin F, Michel C, Sheppard R, Montigny M, Lepage S, Nguyen V, Behloul H, Pilote L. Gender and other disparities in referral to specialized heart failure clinics following emergency department visits. *J Womens Health* 2013;**22**:526–531.
- Motiejūnaitė J, Akiyama E, Cohen-Solal A, Maggioni AP, Mueller C, Choi DJ, Kavolūnienė A, Čelutkienė J, Parenica J, Lassus J, Kajimoto K, Sato N, Miró O, Peacock WF, Matsue Y, Voors AA, Lam CSP, Ezekowitz JA, Ahmed A, Fonarow GC, Gayat E, Regitz-Zagrosek V, Mebazaa A. The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. *Eur Heart J* 2020;**41**:1357–1364.
- Dewan P, Rorth R, Jhund PS, Shen L, Raparelli V, Petrie MC, Abraham WT, Desai AS, Dickstein K, Køber L, Mogensen UM, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, McMurray JJV. Differential impact of heart failure with reduced ejection fraction on men and women. *J Am Coll Cardiol* 2019;**73**:29–40.
- Dewan P, Rorth R, Raparelli V, Campbell RT, Shen L, Jhund PS, Petrie MC, Anand IS, Carson PE, Desai AS, Granger CB, Køber L, Komajda M, McKelvie RS, O'Meara E, Pfeffer MA, Pitt B, Solomon SD, Swedberg K, Zile MR, McMurray JJV. Sex-related differences in heart failure with preserved ejection fraction. *Circ Heart Fail* 2019;**12**:e006539.
- Leo I, Nakou E, de Marvao A, Wong J, Bucciarelli-Ducci C. Imaging in women with heart failure: sex-specific characteristics and current challenges. *Card Fail Rev* 2022;**8**:e29.
- Suthahar N, Meems LMG, Ho JE, de Boer RA. Sex-related differences in contemporary biomarkers for heart failure: a review. *Eur J Heart Fail* 2020;**22**:775–788.
- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, de Boer RA, Christian Schulze P, Abdelhamid M, Aboyans V, Adamopoulos S, Anker SD, Arbelo E, Asteggiano R, Bauersachs J, Bayes-Genis A, Borger MA, Budts W, Cikes M, Damman K, Delgado V, Dendale P, Dilaveris P, Drexel H, Ezekowitz J, Falk V, Fauchier L, Filippatos G, Fraser A, Frey N, Gale CP, Gustafsson F, Harris J, Jung B, Janssens S, Jessup M, Konradi A, Kotecha D, Lambrinou E, Lancellotti P, Landmesser U, Leclercq C, Lewis BS, Leyva F, Linhart A, Løchen M-L, Lund LH, Mancini D, Masip J, Milicic D, Mueller C, Nef H, Nielsen J-C, Neubeck L, Noutsias M, Petersen SE, Sonia Petronio A, Ponikowski P, Prescott E, Rakisheva A, Richter DJ, Schlyakhto E, Seferovic P, Senni M, Sitges M, Sousa-Uva M, Tocchetti CG, Touyz RM, Tschoepe C, Waltenberger J, Adamo M, Baumbach A, Böhm M, Burri H, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gardner RS, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;**42**:3599–3726.
- Jones R, Varian F, Alabed S, Morris P, Rothman A, Swift AJ, Lewis N, Kyriacou A, Wild JM, Al-Mohammad A, Zhong L, Dastidar A, Storey RF, Swoboda PP, Bax JJ, Garg P. Meta-analysis of echocardiographic quantification of left ventricular filling pressure. *ESC Heart Fail* 2021;**8**:566–576.
- Garg P, Gosling R, Swoboda P, Jones R, Rothman A, Wild JM, Kiely DG, Condliffe R, Alabed S, Swift AJ. Cardiac magnetic resonance identifies raised left ventricular filling pressure: prognostic implications. *Eur Heart J* 2022;**43**:2511–2522.
- Garg P, Lewis RA, Johns CS, Swift AJ, Capener D, Rajaram S, Thompson AAR, Condliffe R, Elliot CA, Charalampopoulos A, Hameed AG, Rothman A, Wild JM, Kiely DG. Cardiovascular magnetic resonance predicts all-cause mortality in pulmonary hypertension associated with heart failure with preserved ejection fraction. *Int J Cardiovasc Imaging* 2021;**37**:3019–3025.
- Garg P, Assadi H, Jones R, Chan WB, Metherall P, Thomas R, van der Geest R, Swift AJ, Al-Mohammad A. Left ventricular fibrosis and hypertrophy are associated with mortality in heart failure with preserved ejection fraction. *Sci Rep* 2021;**11**:617.
- Assadi H, Jones R, Swift AJ, Al-Mohammad A, Garg P. Cardiac MRI for the prognostication of heart failure with preserved ejection fraction: a systematic review and meta-analysis. *Magn Reson Imaging* 2021;**76**:116–122.
- Gosling R, Swift AJ, Garg P. Cardiovascular magnetic resonance can improve the precision for left ventricular filling pressure assessment. *Eur Heart J* 2023;**44**:427–428.
- Grafton-Clarke C, Garg P, Swift AJ, Alabed S, Thomson R, Aung N, Chambers B, Klassen J, Levelt E, Farley J, Greenwood JP, Plein S, Swoboda PP. Cardiac magnetic resonance left ventricular filling pressure is linked to symptoms, signs and prognosis in heart failure. *ESC Heart Fail* 2023;**10**:3067–3076.
- Garg P, Javed W, Assadi H, Alabed S, Grafton-Clarke C, Swift AJ, Williams G, Al-Mohammad A, Sawh C, Vassiliou VS, Khanji MY, Ricci F, Greenwood JP, Plein S, Swoboda P. An acute increase in left atrial volume and left ventricular filling pressure during adenosine administered myocardial hyperaemia: CMR First-Pass Perfusion Study. *BMC Cardiovasc Disord* 2023;**23**:246.
- Backhaus SJ, Schulz A, Lange T, Evertz R, Kowallick JT, Hasenfuß G, Schuster A. Rest and exercise-stress estimated pulmonary capillary wedge pressure using real-time free-breathing cardiovascular magnetic resonance imaging. *J Cardiovasc Magn Reson* 2024;**26**:101032.
- Humbert M, Kovacs G, Hoepfer MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S, Scherzmann M, Dinh-Xuan AT, Bush A, Abdelhamid M, Aboyans V, Arbustini E, Asteggiano R, Barberà JA, Beghetti M, Čelutkienė J, Cikes M, Condliffe R, de Man F, Falk V, Fauchier L, Gaine S, Galié N, Gin-Sing W, Granton J, Grünig E, Hassoun PM, Hellemons M, Jaarsma T, Kjellström B, Klok FA, Konradi A, Koskinas KC, Kotecha D, Lang I, Lewis BS, Linhart A, Lip GYH, Løchen ML, Mathioudakis AG, Mindham R, Moledina S, Naeije R, Nielsen JC, Olschewski H, Opitz I, Petersen SE, Prescott E, Rakisheva A, Reis A, Ristić AD, Roche N, Rodrigues R, Selton-Suty C, Souza R, Swift AJ, Touyz RM, Ulrich S, Wilkins MR, Wort SJ. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J* 2022;**43**:3618–3731.

23. Epps HV, Astudillo O, Martin YDP, Marsh J. The Sex and Gender Equity in Research (SAGER) guidelines: implementation and checklist development. *Eur Sci Ed* 2022;**48**: e86910.
24. Goodyear MDE, Krleza-Jeric K, Lemmens T. The Declaration of Helsinki. *BMJ* 2007; **335**:624–625.
25. Swift AJ, Rajaram S, Hurdman J, Hill C, Davies C, Sproson TW, Morton AC, Capener D, Elliot C, Condliffe R, Wild JM, Kiely DG. Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry. *JACC Cardiovasc Imaging* 2013;**6**:1036–1047.
26. Kramer CM, Barkhausen J, Bucciarelli-Ducci C, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. *J Cardiovasc Magn Reson* 2020;**22**:17.
27. Kawel-Boehm N, Hetzel SJ, Ambale-Venkatesh B, Captur G, Francois CJ, Jerosch-Herold M, Salerno M, Teague SD, Valsangiaco-Buechel E, van der Geest RJ, Bluemke DA. Reference ranges ('normal values') for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update. *J Cardiovasc Magn Reson* 2020;**22**:87.
28. Fung ASY, Soundappan D, Loewenstein DE, Playford D, Strange G, Kozor R, Otton J, Ugander M. Prognostic association supports indexing size measures in echocardiography by body surface area. *Sci Rep* 2023;**13**:19390.
29. Ristow B, Ali S, Na B, Turakhia MP, Whooley MA, Schiller NB. Predicting heart failure hospitalization and mortality by quantitative echocardiography: is body surface area the indexing method of choice? The Heart and Soul Study. *J Am Soc Echocardiogr* 2010;**23**: 406–413.
30. Nassiri Camara EJ, do Prado Valladares FR, Key NK, Santana PF, Kawaoka JR, Campos TH, Santana MRO, Cunha AC, Sampaio DS, Santana GP, Brito LGS, Dourado NOC, Nascimento SJ, Lira APAL, do Nascimento NN, Dos Santos RPF, Rocha SRF, Machado TG. Indexing of left atrial volume by body surface area and height in a Brazilian population without previous heart disease and with a normal heart on echocardiography. Behavior in obese and overweight patients. *Cardiol Cardiovasc Med* 2023; **7**:25–31.
31. Davis EF, Crousillat DR, He W, Andrews CT, Hung JW, Danik JS. Indexing left atrial volumes: alternative indexing methods better predict outcomes in overweight and obese populations. *JACC Cardiovasc Imaging* 2022;**15**:989–997.
32. Faulkner JL. Obesity-associated cardiovascular risk in women: hypertension and heart failure. *Clin Sci* 2021;**135**:1523–1544.
33. Nemes A, Kormányos Á, Ruzsa Z, Achim A, Ambrus N, Lengyel C. Simultaneously assessed three-dimensional speckle-tracking echocardiography-derived left ventricular and left atrial volumes are associated in healthy adults—findings from the MAGYAR-Healthy Study. *J Clin Med* 2023;**12**:4153.
34. Kanagala P, Cheng ASH, Singh A, McAdam J, Marsh AM, Arnold JR, Squire IB, Ng LL, McCann GP. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in heart failure with preserved ejection fraction—implications for clinical trials. *J Cardiovasc Magn Reson* 2018;**20**:4.
35. Kittleson MM, Panjra GS, Amancherla K, Davis LL, Deswal A, Dixon DL, Januzzi JL, Yancy CW. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol* 2023;**81**:1835–1878.
36. Backhaus SJ, Schulz A, Lange T, Schmidt-Schweda LS, Evertz R, Kowallick J, Hasenfuß G, Schuster A. Real-time cardiovascular magnetic resonance imaging for non-invasive characterisation of heart failure with preserved ejection fraction: final outcomes of the HFpEF stress trial. *Clin Res Cardiol* 2024;**113**:496–508.
37. Schulz A, Lange T, Evertz R, Kowallick JT, Hasenfuß G, Backhaus SJ, Schuster A. Sex-specific impairment of cardiac functional reserve in HFpEF. *JACC Adv* 2023;**2**: 100327.
38. Rosch S, Kresoja KP, Besler C, Fengler K, Schöber AR, von Roeder M, Lücke C, Gutberlet M, Klingel K, Thiele H, Rommel K-P, Lurz P. Characteristics of heart failure with preserved ejection fraction across the range of left ventricular ejection fraction. *Circulation* 2022;**146**:506–518.
39. Giusca S, Steen H, Montenbruck M, Patel AR, Pieske B, Erley J, Kelle S, Korosoglou G. Multi-parametric assessment of left ventricular hypertrophy using late gadolinium enhancement, T1 mapping and strain-encoded cardiovascular magnetic resonance. *J Cardiovasc Magn Reson* 2021;**23**:92.
40. Maceira AM, Mohiaddin RH. Cardiovascular magnetic resonance in systemic hypertension. *J Cardiovasc Magn Reson* 2012;**14**:28.
41. Bohbot Y, Renard C, Manrique A, Levy F, Maréchaux S, Gerber BL, Tribouilloy C. Usefulness of cardiac magnetic resonance imaging in aortic stenosis. *Circ Cardiovasc Imaging* 2020;**13**:e010356.
42. Mishra S, Kass DA. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. *Nat Rev Cardiol* 2021;**18**:400–423.
43. Samak M, Fatullayev J, Sabashnikov A, Zeriuoh M, Schmack B, Farag M, Popov A-F, Dohmen PM, Choi Y-H, Wahlers T, Weymann A. Cardiac hypertrophy: an introduction to molecular and cellular basis. *Med Sci Monit Basic Res* 2016;**22**:75–79.
44. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. *Circulation* 2000;**102**:470–479.
45. Schiattarella GG, Hill TM, Hill JA. Is load-induced ventricular hypertrophy ever compensatory? *Circulation* 2017;**136**:1273–1275.
46. Solmaz H, Ozdogan O. Left atrial phasic volumes and functions changes in asymptomatic patients with sarcoidosis: evaluation by three-dimensional echocardiography. *Acta Cardiol* 2022;**77**:782–790.
47. Kasapkara HA, Şentürk A, Bilen E, Duran Karaduman B, Ayhan H, Özen MB, Durmaz T, Keleş T, Bozkurt E. The usefulness of left atrial volume index and left ventricular mass index in determining subclinical cardiac involvement in patients with early-stage sarcoidosis. *Ir J Med Sci* 2016;**185**:617–621.
48. Geenty P, Sivapathan S, Stefani LD, Zada M, Boyd A, Richards D, Kwok F, Thomas L. A novel echocardiographic risk score for light-chain amyloidosis. *Eur Heart J Open* 2023;**3**: oead040.
49. Berthelot E, Jourdain P, Bailly MT, Bouchachi A, Gellen B, Rouquette A, Damy T, Hervé P, Chemla D, Assayag P. Echocardiographic evaluation of left ventricular filling pressure in patients with heart failure with preserved ejection fraction: usefulness of inferior vena cava measurements and 2016 EACVI/ASE recommendations. *J Card Fail* 2020;**26**: 507–514.
50. Rozwadowska K, Raczak G, Sikorska K, Fijałkowski M, Kozłowski D, Daniłowicz-Szymanowicz L. Influence of hereditary haemochromatosis on left ventricular wall thickness: does iron overload exacerbate cardiac hypertrophy? *Folia Morphol* 2019;**78**:746–753.
51. Wierzbowska-Drabik K, Kasprzak JD, Haberka M, Peteiro J, Re F, D'Alfonso MG, Mori F, Palinkas ED, Agoston G, Varga A, Djordjevic-Dikic A, Tesic M, Zagatina A, Rodriguez-Zanella H, Simova I, Merli E, Morrone D, D'Andrea A, Camarozano AC, Reisenhofer B, Prota C, Citro R, Celutkiene J, Boshchenko A, Ciampi Q, Picano E. Left atrial volume changes during exercise stress echocardiography in heart failure and hypertrophic cardiomyopathy. *Hellenic J Cardiol* 2022;**67**:9–18.
52. Backhaus SJ, Lange T, George EF, Hellenkamp K, Gertz RJ, Billing M, Wachter R, Steinmetz M, Kutty S, Raaz U, Lotz J, Friede T, Uecker M, Hasenfuß G, Seidler T, Schuster A. Exercise stress real-time cardiac magnetic resonance imaging for non-invasive characterization of heart failure with preserved ejection fraction: the HFpEF-stress trial. *Circulation* 2021;**143**:1484–1498.
53. McKechnie DGJ, O'Nions E, Bailey J, Hobbs L, Gillespie F, Petersen I. Transgender identity in young people and adults recorded in UK primary care electronic patient records: retrospective, dynamic, cohort study. *BMJ Med* 2023;**2**:e000499.